Vincent Chen
University of Michigan Medical School
Appearances
DateMay 8, 2023BACKGROUND: The glucagon-like-receptor (GLP)-1 agonist semaglutide has demonstrated therapeutic efficacy on clinical endpoints in a recent phase 2 clinical trial in patients with non-alcoholic steatohepatitis (NASH)(Newsome et al. NEJM, 2021)…Presenter
Speakers
University of Michigan Medical School- DateMay 6, 2023The rising prevalence of non-alcoholic fatty liver disease (NAFLD) will result in increased referrals to gastroenterology and hepatology units…
Presenter
Speakers
University of Michigan Medical School 
DateMay 18, 2024RISK STRATIFICATION IN REFERRALS FOR MASLD: GI ASSESSMENTModerators
Weill Cornell Medical CollegeUniversity of Michigan Medical SchoolSpeakers
- DateMay 20, 2024Background: Body composition measures including sarcopenia, visceral fat volume, and subcutaneous fat volume are associated with fibrosis stage in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)…
Presenter
University of Michigan Medical SchoolSpeakers
